PPARG and fatty liver disease: In the liver, CLE supplementation decreased the expression of lipogenic genes, such as Acaca (ACC1), Fasn, Scd1, Srebf1a, Srebf1c, Srebf2, and Pparg while it increased the FAO-related gene, Cpt1a. Of note, PPARγ promotes hepatic steatosis while decreased PPARγ function protects against hepatic steatosis in diet-induced obesity and insulin resistance mice [27,28].